Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

References

• SievertDMRicksPEdwardsJRAntimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010Infect Control Hosp Epidemiol201334111423221186
   PubMed Web of Science ®Google Scholar
• HamptonTReport reveals scope of US antibiotic resistance threatJAMA2013310161661166324150445
   PubMed Web of Science ®Google Scholar
• ZilberbergMDShorrAFSecular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009Infect Control Hosp Epidemiol201334994094623917908
   PubMed Web of Science ®Google Scholar
• BabinchakTBadalRHobanDTrends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005–2010Diagn Microbiol Infect Dis201376337938123541118
   PubMed Web of Science ®Google Scholar
• NicolleLEA practical guide to antimicrobial management of complicated urinary tract infectionDrugs Aging200118424325411341472
   PubMed Web of Science ®Google Scholar
• PallettAHandKComplicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteriaJ Antimicrob Chemother201065suppl 3iii25iii3320876625
   PubMed Web of Science ®Google Scholar
• WagenlehnerFMUmehOSteenbergenJYuanGDarouicheROCeftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)Lancet201538599811949195625931244
   PubMed Web of Science ®Google Scholar
• SolomkinJSMazuskiJEBradleyJSDiagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of AmericaClin Infect Dis201050213316420034345
   PubMed Web of Science ®Google Scholar
• SolomkinJHershbergerEMillerBCeftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)Clin Infect Dis201560101462147125670823
   PubMed Web of Science ®Google Scholar
• ToussaintKAGallagherJCBeta-lactam/beta-lactamase inhibitor combinations: from then to nowAnn Pharmacother2015491869825361682
   PubMed Web of Science ®Google Scholar
• BushKJacobyGAUpdated functional classification of beta-lactamasesAntimicrob Agents Chemother201054396997619995920
   PubMed Web of Science ®Google Scholar
• LiscioJLMahoneyMVHirschEBCeftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infectionsInt J Antimicrob Agents201546326627126143591
   PubMed Web of Science ®Google Scholar
• MoyaBZamoranoLJuanCPerezJLGeYOliverAActivity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patientsAntimicrob Agents Chemother20105431213121720086158
   PubMed Web of Science ®Google Scholar
• LivermoreDMMultiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?Clin Infect Dis200234563464011823954
   PubMed Web of Science ®Google Scholar
• HirschEBTamVHImpact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomesExpert Rev Pharmacoecon Outcomes Res201010444145120715920
   PubMed Web of Science ®Google Scholar
• KayeKSPogueJMInfections caused by resistant Gram-negative bacteria: epidemiology and managementPharmacotherapy2015351094996226497481
   PubMed Web of Science ®Google Scholar
• NguyenHMShierKLGraberCJDetermining a clinical framework for use of cefepime and beta-lactam/beta-lactamase inhibitors in the treatment of infections caused by extended-spectrum-beta-lactamase-producing EnterobacteriaceaeJ Antimicrob Chemother201469487188024265230
   PubMed Web of Science ®Google Scholar
• ParkSHChoiSMChangYKThe efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coliJ Antimicrob Chemother201469102848285624928854
   PubMed Web of Science ®Google Scholar
• Rodriguez-BanoJNavarroMDRetamarPPiconEPascualABeta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohortsClin Infect Dis201254216717422057701
   PubMed Web of Science ®Google Scholar
• HirschEBGuoBChangKTAssessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniaeJ Infect Dis2013207578679323242537
   PubMed Web of Science ®Google Scholar
• HirschEBTamVHDetection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infectionJ Antimicrob Chemother20106561119112520378670
   PubMed Web of Science ®Google Scholar
• van DuinDKayeKSNeunerEABonomoRACarbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesDiagn Microbiol Infect Dis201375211512023290507
   PubMed Web of Science ®Google Scholar
• ZasowskiEJRybakJMRybakMJThe beta-lactams strike back: ceftazidime-avibactamPharmacotherapy201535875577026289307
   PubMed Web of Science ®Google Scholar
• PheKJohnsonMLPalmerHRTamVHValidation of a model to predict the risk of nephrotoxicity in patients receiving colistinAntimicrob Agents Chemother201458116946694825136012
   PubMed Web of Science ®Google Scholar
• PheKLeeYMcDaneldPMIn vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapyAntimicrob Agents Chemother20145852740274624566187
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. [webpage on the Internet]Zerbaxa Prescribing Information Available from: http://www.zerbaxa.com/pdf/PrescribingInformation.pdfAccessed February 26, 2016
   Google Scholar
• ChoJCFiorenzaMAEstradaSJCeftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combinationPharmacotherapy201535770171526133315
   PubMed Web of Science ®Google Scholar
• BulikCCTessierPRKeelRASutherlandCANicolauDPIn vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organismsAntimicrob Agents Chemother201256154454922064538
   PubMed Web of Science ®Google Scholar
• CraigWAAndesDRIn vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic miceAntimicrob Agents Chemother20135741577158223274659
   PubMed Web of Science ®Google Scholar
• MoyaBZamoranoLJuanCGeYOliverAAffinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosaAntimicrob Agents Chemother20105493933393720547785
   PubMed Web of Science ®Google Scholar
• SaderHSRhombergPRFarrellDJJonesRNAntimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypesAntimicrob Agents Chemother20115552390239421321149
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards InstitutePerformance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. M100-S25Wayne, PAClinical and Laboratory Standards Institute2015
   Google Scholar
• FarrellDJFlammRKSaderHSJonesRNAntimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011–2012)Antimicrob Agents Chemother201357126305631024100499
   PubMed Web of Science ®Google Scholar
• SnydmanDRMcDermottLAJacobusNVActivity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolatesAntimicrob Agents Chemother20145821218122324277025
   PubMed Web of Science ®Google Scholar
• GeYWhitehouseMJFriedlandITalbotGHPharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusionsAntimicrob Agents Chemother20105483427343120457817
   PubMed Web of Science ®Google Scholar
• MillerBHershbergerEBenzigerDTrinhMFriedlandIPharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending dosesAntimicrob Agents Chemother20125663086309122450972
   PubMed Web of Science ®Google Scholar
• WooleyMMillerBKrishnaGHershbergerEChandorkarGImpact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactamAntimicrob Agents Chemother20145842249225524492369
   PubMed Web of Science ®Google Scholar
• MacGowanAPNoelARTomaselliSGNichollsDBowkerKEPharmacodynamics of ceftolozane plus tazobactam studied in an in vitro pharmacokinetic model of infectionAntimicrob Agents Chemother201560151552126552975
   PubMed Web of Science ®Google Scholar
• FDA [webpage on the Internet]FDA Drug Safety Communication: FDA Cautions about Dose Confusion and Medication Errors for Antibacterial Drug Zerbaxa (Ceftolozane and Tazobactam) Available from: http://www.fda.gov/Drugs/DrugSafety/ucm445919.htmAccessed January 7, 2016
   Google Scholar
• SpellbergBBrassEPNoninferiority doesn’t mean not inferiorClin Infect Dis201662452552626486703
   PubMed Web of Science ®Google Scholar
• SolomkinJSHershbergerEEckmannCResponse to Spellberg and BrassClin Infect Dis201662452626486708
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [webpage on the Internet]Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (ASPECT-NP). Identifier NCT020707572015 Available from: https://clinicaltrials.gov/ct2/show/NCT02070757?term=ceftolozane&rank=2Accessed January 7, 2016
   Google Scholar
• XiaoAJMillerBWHuntingtonJANicolauDPCeftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumoniaJ Clin Pharmacol2016561566626096377
   PubMed Web of Science ®Google Scholar
• LucastiCHershbergerEMillerBMulticenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infectionsAntimicrob Agents Chemother20145895350535724982069
   PubMed Web of Science ®Google Scholar
• SawyerRGClaridgeJANathensABTrial of short-course antimicrobial therapy for intraabdominal infectionN Engl J Med2015372211996200525992746
   PubMed Web of Science ®Google Scholar
• CluckDLewisPStayerBSpiveyJMoormanJCeftolozane-tazobactam: a new-generation cephalosporinAm J Health Syst Pharm201572242135214626637512
   PubMed Web of Science ®Google Scholar
• BoucherHWTalbotGHBenjaminDKJr10 x ‘20 progress – development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of AmericaClin Infect Dis201356121685169423599308
   PubMed Web of Science ®Google Scholar
• BoucherHWTalbotGHBradleyJSBad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaClin Infect Dis200948111219035777
   PubMed Web of Science ®Google Scholar